Atherosclerosis and Lipid Lowering: is there a Need for New Agents?

Leonardo Roever1, Elmiro Santos Resende2 and Giuseppe Biondi-Zoccai2,3

1Department of Clinical Research, Federal University of Uberlandia, Brazil
2Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
3Eleonora Lorillard Spencer Cenci Foundation, Rome, Italy

*Corresponding author: Leonardo Roever, Department of Clinical Research, Av. Pará, 1720-Bairro Umuarama, Uberlandia-MG-CEP 38400-902, Brazil, Tel: 553488038878, E-mail: leonardoroever@hotmail.com

Received date: Sep 15, 2015; Accepted date: May 10, 2016; Published date: May 17, 2016

Copyright: © 2016 Roever L et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Cardiovascular disease (CVD) is the leading cause of death worldwide. Among well-known risk factors, such as visceral obesity, sedentary lifestyle, metabolic syndrome, smoking, hypertension, age, gender, family history of heart attacks, diabetes, low levels HDL-C, high levels of LDL-C and total cholesterol are very strong predictors of CVD events and death[1-5].

In recent years, there have been significant advances in the elucidation of biomarkers of atherosclerotic disease, and also their pathogenesis, prevention and treatment. Atherosclerosis is a systemic inflammatory disease characterized by on-going progression in response to systemic risk factors and local pro-atherogenic stimuli that leads to acute myocardial infarction, stroke and lower limb ischemia [6].

An intriguing question is what is the real level cardio protective LDL cholesterol? Especially for patients with a history of heart attack, peripheral artery disease, or stroke: is 70 mg/dL, which is currently recommended or should down to levels of 40 or 30 mg/dL?

Statins has substantially reduced CVD events around the world and is recommended as first-line therapy for CVD management. However, a need for other lipid-lowering agents, because some patients do not tolerate statins due to adverse events, or cannot reach LDL-C level desired because of high levels of LDL-C, or patients with very high risk cardiovascular events need more intensive reduction therapy [7-9]. Can we pay the benefits of these new agents when statins are effective and inexpensive?

Zhang et al. reported a meta-analysis study to evaluate the safety and efficacy of anti-PCSK9 antibodies in randomized, controlled trials (RCTs). Twenty-five RCTs encompassing 12,200 patients were included. The study showing largely no significant difference between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced rates of death (relative risk (RR): 0.43, 95% CI: 0.19 to 0.96, P=0.04) and an increased rate of injection-site reactions (RR: 1.48, 95% CI: 1.05 to 2.09, P=0.02);

evolocumab reduced the rate of abnormal liver function (RR: 0.43, 95% CI: 0.20 to 0.93, P=0.03), both compared with placebo. Evolocumab and alirocumab substantially reduced the LDL-C level by over 50%, increased the HDL-C level, and resulted in favourable changes in other lipids [9].

New agents, as well as prevention programs should be implemented in order to decrease the morbidity and mortality caused by atherosclerotic events.

References